Ficsor G, Bordás S, Wade S M, Muthiani E, Wertz G F, Zimmer D M
Mutat Res. 1977;48(1):1-15. doi: 10.1016/0027-5107(77)90185-3.
The mutagenicity of captan and of streptozotocin was tested in vivo by reversion of hisG46 base-pair substitution histidine auxotrophs of Salmonella typhimurium in the peritoneal cavity or in blood, plasma or urine of rats or mice. Genetic response was determined by the frequency of revertants (quantitative test) or by the number of revertants per plate (semiquantitative test). In quantitative HMA captan gave negative results following 3 hourly 500 mg/kg s.c. doses or 1000 mg/kg oral dose in mice with the hisG46 mutant or 2000 mg/kg oral dose in rats with the hisG46, uvrB (TA1950) mutant. The positive control SZN induced many reversions at 0.5 mg/kg i.p. or 10 or 100 mg/kg oral doses. In semiquantitative in vivo blood or urine assays captan gave negative results after a 250 mg/kg oral dose with hisG46. SZN in the same experiment gave positive results in both semiquantitative and quantitative in vivo blood assays following 1000 mg/kg i.p. or 2000 mg/kg oral doses in the rat with TA1950. Rat blood mixed with captan for 45 min before adding TA1950 cells inactivated 1000 mug captan/ml but not 5000 mg/ml in the semiquantitative test. Corresponding figures in the quantitative test were 500 mu/ml and 1000 mug/ml. Rat plasma inactivated the mutagenicity of about 10 times less captan than rat blood. Human blood inactivated about as much captan as rat blood. The mutagenicity of captan was inactivated more efficiently than of SZN by blood. The results of the experiments suggested that captan's mutagenicity is probably inactivated by glutathione of the erythrocytes. Rat S-9 liver microsomal fraction also strongly decreased captan's mutagenicity in a semiquantitative test with the R factor, uvrB, hisG46 (TA100) mutant.
通过鼠伤寒沙门氏菌hisG46碱基对取代组氨酸营养缺陷型菌株在大鼠或小鼠腹腔、血液、血浆或尿液中的回复突变,对克菌丹和链脲佐菌素的致突变性进行了体内测试。通过回复子频率(定量测试)或每平板回复子数量(半定量测试)来确定遗传反应。在定量HMA中,对于携带hisG46突变的小鼠,皮下注射3小时500mg/kg剂量或口服1000mg/kg剂量,以及对于携带hisG46、uvrB(TA1950)突变的大鼠,口服2000mg/kg剂量后,克菌丹均给出阴性结果。阳性对照链脲佐菌素腹腔注射0.5mg/kg或口服10或100mg/kg剂量时诱导出许多回复突变。在半定量体内血液或尿液检测中,口服250mg/kg剂量hisG46后克菌丹给出阴性结果。在同一实验中,对于携带TA1950的大鼠,腹腔注射1000mg/kg或口服2000mg/kg剂量后,链脲佐菌素在半定量和定量体内血液检测中均给出阳性结果。在半定量测试中,在添加TA1950细胞前将大鼠血液与克菌丹混合45分钟,1000μg/ml克菌丹可被灭活,但5000mg/ml不能。定量测试中的相应数值为500μg/ml和1000μg/ml。大鼠血浆使克菌丹致突变性失活的能力比大鼠血液约低10倍。人血使克菌丹失活的能力与大鼠血液大致相同。血液使克菌丹的致突变性比链脲佐菌素更有效地失活。实验结果表明,克菌丹的致突变性可能被红细胞中的谷胱甘肽失活。在使用R因子、uvrB、hisG46(TA100)突变体的半定量测试中,大鼠S-9肝微粒体组分也强烈降低了克菌丹的致突变性。